BiotechTube
PlaqueTec

PlaqueTec

Cambridge, United Kingdom· Est.
plaquetec.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

PlaqueTec is a private, pre-revenue diagnostics company founded in 2014 in Cambridge, UK, focused on endotyping Coronary Artery Disease. Its core innovation is a novel catheter-based Liquid Biopsy System that captures trans-plaque biomarker gradients during coronary angiography, generating unique biological data from the site of disease. The company is currently running the BIOPATTERN trial to build a biomarker database from 300 CAD patients, aiming to identify new drug targets and enable stratified clinical trials for pharmaceutical partners. PlaqueTec's approach seeks to move CAD treatment from a one-size-fits-all model to a precision medicine paradigm.

CardiovascularCoronary Artery Disease

Technology Platform

Proprietary catheter-based Liquid Biopsy System (LBS) for intra-coronary blood sampling to measure trans-plaque biomarker gradients, integrated with multi-omic analysis (proteomics, genomics) and clinical data for patient endotyping.

Funding History

2
Total raised:$10M
Series A$8M
Seed$2M

Opportunities

The massive, underserved global CAD market and high failure rate of one-size-fits-all therapies create a major need for precision medicine tools.
PlaqueTec's unique localized sampling data can de-risk pharmaceutical R&D by identifying novel targets and enabling stratified clinical trials, positioning the company for lucrative pharma partnerships and potential companion diagnostic development.

Risk Factors

Key risks include the failure of the BIOPATTERN trial to identify validated, actionable endotypes, challenging the core technology thesis.
Commercial adoption risk is high, as convincing pharma and clinicians to use an invasive procedural tool requires demonstrating clear superior value over less invasive alternatives.
The company also faces ongoing funding risk as a pre-revenue startup.

Competitive Landscape

PlaqueTec's direct competition is limited due to its novel invasive sampling approach. However, it competes indirectly with companies developing non-invasive CAD diagnostics (e.g., advanced blood biomarkers, imaging AI) and large pharma internal precision medicine efforts. Its defensibility lies in the unique, site-specific biological data its LBS captures, which is not replicable via peripheral blood tests alone.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →